Inspire Medical Systems Analysts Lower Their Forecasts After Q2 Results
Aug 5, 2025, 2:25 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The significant reduction in guidance and steep share price drop typically indicates bearish sentiment. Historical examples show similar cases led to ongoing negative price trends.
AI summary
What happened, with direct paths to the underlying reporting
INSP reported Q2 earnings of $0.45, surpassing estimates of $0.21. Company lowered FY2025 EPS guidance significantly to $0.40-$0.50. Sales guidance for FY2025 reduced to $900 million-$910 million. Analysts have downgraded price targets for INSP following disappointing guidance. Shares fell 40.6% to $77.14 after the announcement.
INSP reported Q2 earnings of $0.45, surpassing estimates of $0.21.
Company lowered FY2025 EPS guidance significantly to $0.40-$0.50.
Sales guidance for FY2025 reduced to $900 million-$910 million.
Analysts have downgraded price targets for INSP following disappointing guidance.
Shares fell 40.6% to $77.14 after the announcement.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
INSP delivered a solid Q2 beat with EPS and revenue above expectations and raised FY2026 guidance. The updates imply stronger demand and improving profitability as reimbursement d…
INSP stock surged due to a Medicare reimbursement increase announcement. Analyst upgrade from 'Hold' to 'Buy' with a $110 target price. Stock is down 38% YTD, presenting volatilit…
Stifel upgrades INSP to Buy, raising price target to $110. Inspire Medical sees a 50% reimbursement increase for its Inspire V implant. Advertising spending rose 56% in Q3, boosti…